Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), which was reconvened on October 18, 2023, has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2023, as supplemented on September 15, 2023 and September 22, 2023.
The required quorum for the transaction of business at the Annual Meeting is a majority of the voting power of shares of common stock issued and outstanding on the record date. There was less than the required voting power represented in person or by proxy at the meeting. The Annual Meeting will be reconvened on November 16, 2023 at 9:00 a.m. Eastern Time and will continue to be held virtually via live audio-only webcast at www.virtualshareholdermeeting.com/sngx2023.
The record date for determination of stockholders entitled to vote at the reconvened Annual Meeting remains the close of business on July 24, 2023. At the time the Annual Meeting was adjourned, proxies had been submitted by stockholders representing approximately 39.3% of the shares of the Company’s common stock issued and outstanding as of the record date.